Earnings History Data for Panbela Therapeutics Inc. (PBLA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Panbela Therapeutics Inc.

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics Inc., formerly known as Sun BioPharma Inc., is based in MINNEAPOLIS.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
26-03-2024	AH		PBLA	Panbela Therapeutics Inc.	2.00	-65.90	-24.34	0.00	Panbela Therapeutics GAAP EPS of -$65.90 beats by $151.10 [3/26/2024 4:14 PM]	0.63	-0.01 (-1.56%)	0.0	0.0 (0.00%)	0.41 - 477.00	94,545	0	0
Panbela Therapeutics GAAP EPS of -$65.90 beats by $151.10 [3/26/2024 4:14 PM]
09-11-2023	AH		PBLA	Panbela Therapeutics, Inc.	2.81	-2.69	-2.06	-99.99	Panbela Therapeutics GAAP EPS of -$2.69 misses by $0.63 [11/9/2023 4:43 PM]	0.6001	0.02 (3.11%)	0.62	0.04 (6.51%)	0.58 - 295.20	149,131	6,100,000	3,526
Panbela Therapeutics GAAP EPS of -$2.69 misses by $0.63 [11/9/2023 4:43 PM]
10-08-2023	AH		PBLA	Panbela Therapeutics, Inc.	30.89	-7.95	-4.70	-99.99	Panbela Therapeutics GAAP EPS of -$7.95 misses by $3.24 [8/10/2023 4:21 PM]	1.62	-0.07 (-4.14%)	1.61	-0.08 (-4.73%)	1.53 - 1,644.00	72,754	130,000	19,431
Panbela Therapeutics GAAP EPS of -$7.95 misses by $3.24 [8/10/2023 4:21 PM]
04-05-2023	AH	4:10 PM ET (May 4)	PBLA	Panbela Therapeutics, Inc.	6.57	-0.65	-0.49	-10.80	Panbela Therapeutics GAAP EPS of -$0.65 [5/4/2023 4:56 PM]	0.4325	-0.02 (-3.89%)	0.43	-0.02 (-5.00%)	0.32 - 73.82	729,869	8,030,000	50,322
Panbela Therapeutics GAAP EPS of -$0.65 [5/4/2023 4:56 PM]
16-03-2023	AH	4:10 PM ET (Mar 16)	PBLA	Panbela Therapeutics, Inc.	8.17	-5.68	0.00	-10.40	Panbela Therapeutics GAAP EPS of -$5.68 misses by $2.08 [3/16/2023 4:33 PM]	0.4911	-0.17 (-25.59%)	0.58	-0.08 (-12.12%)	0.41 - 87.60	1,702,689	1,010,000	134,867
Panbela Therapeutics GAAP EPS of -$5.68 misses by $2.08 [3/16/2023 4:33 PM]
10-11-2022	AH	4:10 PM ET (Nov 10)	PBLA	Panbela Therapeutics, Inc.	2.53	-0.21	-0.23	-0.16	Panbela Therapeutics GAAP EPS of -$0.21 [11/10/2022 4:19 PM]	0.1153	0.0 (4.06%)	0.12	0.0 (4.51%)	0.10 - 2.40	338,887	530,000	5,142
Panbela Therapeutics GAAP EPS of -$0.21 [11/10/2022 4:19 PM] Panbela Provides Business Update and Reports Q3 2022 Financial Results [Nov-10-22 04:10PM]
15-08-2022	AH	4:05 PM ET (Aug 15)	PBLA	Panbela Therapeutics, Inc.	28.46	-1.51	-0.22	-0.22	Panbela Therapeutics GAAP EPS of -$1.51 [8/15/2022 4:28 PM]	1.07	-0.12 (-10.08%)	0.0	0.0 (0.00%)	0.59 - 2.54	10,608	10,000	0
Panbela Therapeutics GAAP EPS of -$1.51 [8/15/2022 4:28 PM] Panbela Provides Business Update and Reports Q2 2022 Financial Results [Aug-15-22 04:10PM]
12-05-2022	AH	4:05 PM ET (May 12)	PBLA	Panbela Therapeutics, Inc.	22.19	-0.27	-0.26	-0.23	Panbela Therapeutics GAAP EPS of -$0.27 [5/12/2022 5:04 PM]	1.60	0.0 (0.00%)	0.0	0.0 (0.00%)	1.45 - 4.78	1,382	20,000	0
Panbela Therapeutics GAAP EPS of -$0.27 [5/12/2022 5:04 PM] Panbela Provides Business Update and Reports Q1 2022 Financial Results [May-12-22 04:05PM]
24-03-2022	AH	4:15 PM ET (Mar 24)	PBLA	Panbela Therapeutics, Inc.	25.54	-0.26	-0.19	-0.09	Panbela Therapeutics GAAP EPS of -$0.26 [3/24/2022 5:02 PM]	2.08	-0.03 (-1.42%)	0.0	0.0 (0.00%)	1.45 - 4.79	29,644	46,266	0
Panbela to Participate in a Panel Discussion: Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology, at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET [Mar-23-22 08:30AM] Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results [Mar-24-22 04:05PM]
10-11-2021	AH	4:10 PM ET (Nov 10)	PBLA	Panbela Therapeutics, Inc.	28.47	-0.16	-0.27	-0.21	Panbela Therapeutics reports Q3 results [11/10/2021 4:23 PM]	2.08	0.06 (2.97%)	2.02	0.0 (0.00%)	1.91 - 8.80	13,351	80,000	535
Panbela Therapeutics reports Q3 results [11/10/2021 4:23 PM] Panbela Provides Business Update and Reports Q3 2021 Financial Results [Nov-10-21 04:15PM]
11-08-2021	AH	4:10 PM ET (Aug 11)	PBLA	Panbela Therapeutics, Inc.	32.76	-0.22	-0.23	0.00	Panbela Therapeutics reports Q2 results [8/11/2021 4:20 PM]	2.32	-0.08 (-3.33%)	2.39	-0.01 (-0.42%)	2.22 - 9.75	239,929	500,000	6,375
Panbela Therapeutics reports Q2 results [8/11/2021 4:20 PM] Panbela Provides Business Update and Reports Q2 2021 Financial Results [Aug-11-21 04:12PM]
12-05-2021	AH	After the close (May 12)	PBLA	Panbela Therapeutics, Inc.	40.76	-0.23	0.00	0.00	Panbela Therapeutics reports Q1 results [5/12/2021 4:18 PM]	3.85	-0.15 (-3.83%)	4.17	0.01 (0.24%)	2.37 - 10.00	19,569	40,000	200
Panbela Therapeutics reports Q1 results [5/12/2021 4:18 PM] Panbela Therapeutics, Inc. to Host Earnings Call [May-12-21 02:30PM] Panbela Provides Business Update and Reports Q1 2021 Financial Results [May-12-21 04:10PM]
25-03-2021	AH	After the close (Mar 25)	PBLA	Panbela Therapeutics, Inc.	42.84	-0.09	0.00	0.00	Panbela Therapeutics reports Q4 results [3/25/2021 4:58 PM]	4.23	0.03 (0.71%)	4.10	-0.10 (-2.38%)	2.37 - 10.00	13,036	20,000	10,086
Panbela Therapeutics reports Q4 results [3/25/2021 4:58 PM] Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results [Mar-25-21 04:10PM] Panbela Therapeutics, Inc. to Host Earnings Call [Mar-25-21 04:30PM] Corrected: Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results [Mar-26-21 08:40AM]